yutong_fei@163.com
收稿:2021-06-11,
修回:2021-10-25,
纸质出版:2022-02-02
移动端阅览
.中医药真实世界研究技术规范——证据质量评价与报告[J].中医杂志,2022,63(03):293-300.
国家药品监督管理局 . 真实世界证据支持药物研发与审评的指导原则(试行) [EB/OL].( 2020-07-17 )[ 2020-12-12 ]. http://www.nmpa.gov.cn/WS04/CL2138/373 175.html http://www.nmpa.gov.cn/WS04/CL2138/373175.html .
国家药品监督管理局 . 中药注册管理专门规定(征求意见稿) [EB/OL].( 2020-04-30 )[ 2020-12-12 ]. https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20200430154501 315.html https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20200430154501315.html .
曾繁典 , 郑荣远 , 詹思延 , 等 . 药物流行病学 [M]. 2版 .北京: 中国医药科技出版社 , 2016 : 80 - 87 .
刘建平 . 循证中医药临床研究方法 [M]. 北京 : 人民卫生出版社 , 2009 : 61 - 68 .
彭晓霞 , 舒啸尘 , 谭婧 , 等 . 基于真实世界数据评价治疗结局的观察性研究设计技术规范 [J]. 中国循证医学杂志 , 2019 , 19 ( 7 ): 779 - 786 .
石舒原 , 赵厚宇 , 周庆欣 , 等 . 真实世界证据与随机对照试验:RCT DUPLICATE项目方法学介绍 [J]. 药物流行病学杂志 , 2020 , 29 ( 3 ): 198 - 205 .
柏柳安宁 , 夏结来 , 王陵 , 等 . 真实世界研究中的常见偏倚及其控制 [J]. 中国临床药理学与治疗学 , 2020 , 25 ( 12 ): 1422 - 1428 .
廖星 , 章轶立 , 谢雁鸣 . 真实世界研究标准:RECORD清单和GRACE清单的解读 [J]. 中国中药杂志 , 2015 , 40 ( 24 ): 4734 - 4738 .
吴晶 , 朱玄 , 刘程宇 . 基于医疗大数据的比较效果研究设计要点述评与应用 [J]. 中国药物经济学 , 2019 , 14 ( 5 ): 26 - 30 .
Medical Dictionary for Regulatory Activities(MedDRA) . MedDRA term selection: points to consider release 4 . 21 [EB/OL].( 2021-09-01 )[ 2021-12-30 ]. https://www.meddra.org/how-to-use/support-documentation/english/wel-come https://www.meddra.org/how-to-use/support-documentation/english/wel-come .
NANCY AD , SEBASTIAN S , BARBARA JM , et al . GRACE principles: recognizing high-quality observational studies of comparative effectiveness [J]. Am J Manag Care , 2010 , 16 ( 6 ) : 467 - 471 .
WELLS G , SHEA B , O'CONNELL D , et al . The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses [EB/OL]. ( 2011-01-01 )[ 2020-12-12 ]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp .
Critical Appraisal Skills Programme . CASP (Case Control Study) checklist [EB/OL].( 2019-01-01 )[ 2020-12-12 ]. https://casp-uk.net/ casp-tools-checklists/ https://casp-uk.net/casp-tools-checklists/ .
COLES B , TYRER F , HUSSEIN H , et al . Development, content validation, and reliability of the Assessment of Real-World Observational Studies (ArRoWS) critical appraisal tool [J]. Ann Epidemiol , 2021 , 55 : 57 - 63 . doi: 10.1016/j.annepidem. 2020. 09.014 http://dx.doi.org/10.1016/j.annepidem.2020.09.014 .
ROSTOM A , DUBÉ C , CRANNEY A , et al . Appendix D. Quality assessment forms: cross-sectional/prevalence study quality [M/OL]// Rockville: Agency for Healthcare Research and Quality (US) , 2004 .( 2004-09-01 ) [2020-12-12] . http:/ / www.ncbi.nlm.nih.gov/books/NBK 35156/ www.ncbi.nlm.nih.gov/books/NBK35156/ .
National Institute for Clinical Excellence . Quality assessment for case series [EB/OL]. ( 2015-01-01 )[ 2020-12-12 ]. http://www.nice.org.uk/guidance/cg3/resources/appendix-4-quality-of-case-series-form2 http://www.nice.org.uk/guidance/cg3/resources/appendix-4-quality-of-case-series-form2 .
The Joanna Briggs Institute . Checklist for Case Series [EB/OL]. ( 2021-04-01 ) [ 2021-06-12 ]. https://jbi.global/critical-appraisal-tools https://jbi.global/critical-appraisal-tools .
Institute of Health Economics . IHE quality appraisal checklist for case series studies [EB/OL]. ( 2016-01-01 ) [ 2021-05-11 ]. https://www.ihe.ca/advanced-sear- ch/ihe-quality-appraisal-checklist-for-case-series-studies https://www.ihe.ca/advanced-sear-ch/ihe-quality-appraisal-checklist-for-case-series-studies .
HIGGINS JPT , GREEN S . Cochrane handbook for systematic reviews of interventions version 5.1.0 [EB/OL].( 2011-03-01 )[ 2020-12-12 ]. http://www.cochrane-handbook.org http://www.cochrane-handbook.org .
MATTHEW P , CHRIS W , DARIO S . RoB 2 . 0 : a revised tool to assess risk of bias in randomized trials[EB/OL].( 2016-11-01 )[ 2021-05-11 ]. https://training.cochrane.org/resource/rob-20-webinar https://training.cochrane.org/resource/rob-20-webinar .
JADAD AR , MOORE RA , CARROLL D , et al . Assessing the quality of reports of randomized clinical trials: is blinding necessary? [J] Control Clin Trials , 1996 , 17 ( 1 ): 1 - 12 .
SLIM K , NINI E , FORESTIER D , et al . Methodological index for non-randomized studies (minors): development and validation of a new instrument [J]. ANZ J Surg , 2003 , 73 ( 9 ): 712 - 716 .
STERNE JA , HERNÁN MA , REEVES BC , et al . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions [J]. BMJ , 2016 , 355 : i4919 . doi: 10.1136/bmj.i4919 http://dx.doi.org/10.1136/bmj.i4919 .
SHEA BJ , GRIMSHAW JM , WELLS GA , et al . Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews [J]. BMC Med Res Methodol , 2007 , 7 : 10 . doi: 10.1186/1471-2288-7-10 http://dx.doi.org/10.1186/1471-2288-7-10 .
LECLERCQ V , HILIGSMANN M , PARISI G , et al . Best-worst scaling identified adequate statistical methods and literature search as the most important items of AMSTAR2 (A measurement tool to assess systematic reviews) [J]. J Clin Epidemiol , 2020 , 128 : 74 - 82 . doi: 10.1016/j.jclinepi.2020.08.011 http://dx.doi.org/10.1016/j.jclinepi.2020.08.011 .
GUYATT GH , OXMAN AD , KUNZ R , et al . What is “quality of evidence” and why is it important to clinicians? [J]. BMJ , 2008 , 336 ( 7651 ): 995 - 998 .
VANDENBROUCKE JP , VON ELM E , ALTMAN DG , et al . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration [J]. Int J Surg , 2014 , 12 ( 12 ): 1500 - 1524 .
BENCHIMOL EI , SMEETH L , GUTTMANN A , et al . The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement [J]. PLoS Med , 2015 , 12 ( 10 ): e1001885 .
聂晓璐 , 武泽昊 , 赵厚宇 , 等 . 使用常规收集医疗卫生数据开展观察性研究的报告规范(药物流行病学版)RECORD-PE规范中文版(上) [J]. 药物流行病学杂志 , 2019 , 28 ( 3 ): 190 - 198,212 .
聂晓璐 , 武泽昊 , 赵厚宇 , 等 . 使用常规收集医疗卫生数据开展观察性研究的报告规范(药物流行病学版)RECORD-PE规范中文版(下) [J]. 药物流行病学杂志 , 2019 , 28 ( 4 ): 263 - 272 .
GAGNIER JJ , KIENLE G , ALTMAN DG , et al . The CARE guidelines: consensus‐based clinical case reporting guideline development [J]. Headache , 2013 , 53 ( 10 ): 1541 - 1547 .
于河 , 杨红 , 刘建平 . 专家临证验案与经验的报告方法: 病例系列研究的设计和质量评价 [J]. 中医杂志 , 2008 , 49 ( 5 ): 407 - 410 .
FU SF , CHENG CW , ZHANG L , et al . Consensus-based recommendations for case report in Chinese medicine (CARC) [J]. Chin J Integr Med , 2016 , 22 ( 1 ): 73 - 79 .
ZWARENSTEIN M , TREWEEK S , GAGNIER JJ , et al . Improving the reporting of pragmatic trials: an extension of the CONSORT statement [J]. BMJ , 2008 , 337 : a2390 . doi: 10.1136/bmj.a2390 http://dx.doi.org/10.1136/bmj.a2390 .
DWAN K , LI T , ALTMAN DG , et al . CONSORT 2010 statement: extension to randomised crossover trials [J]. BMJ , 2019 , 366 : l4378 . doi: 10.1136/bmj.l4378 http://dx.doi.org/10.1136/bmj.l4378 .
SUNITA V , LARISSA S , MARGARET S , et al . CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement [J]. BMJ , 2015 , 350 : h1738 . doi: 10.1136/bmj.h1738 http://dx.doi.org/10.1136/bmj.h1738 .
GAGNIER JJ , BOON H , ROCHON P , et al . Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT Statement [J]. Ann Intern Med , 2006 , 144 ( 5 ): 364 - 367 .
CHENG CW , WU TX , SHANG HC , et al . CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration [J]. Ann Intern Med , 2017 , 167 ( 2 ): 112 - 121 .
LI J , HU JY , ZHAI JB , et al . CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): recommendations, explanation and elaboration [J]. Complement Ther Med , 2019 , 46 : 180 - 188 . doi: 10.1016/j.ctim.2019.08.014 http://dx.doi.org/10.1016/j.ctim.2019.08.014 .
KWAKKENBOS L , IMRAN M , MCCALL SJ , et al . CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration [J]. BMJ , 2021 , 373 : n857 . doi: 10.1136/bmj.n857 http://dx.doi.org/10.1136/bmj.n857 .
VLAHOV D . Transparent reporting of evaluations with nonrandomized designs (TREND) [J]. J Urban Health , 2004 , 81 ( 2 ): 163 - 164 .
PAGE MJ , MCKENZIE JE , BOSSUYT PM , et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [J]. BMJ , 2021 , 372 : n71 . doi: 10.1136/bmj.n71 http://dx.doi.org/10.1136/bmj.n71 .
ZHANG X , TAN R , LAM WC , et al . PRISMA (preferred reporting items for systematic reviews and meta-analyses) extension for Chinese herbal medicines 2020 (PRISMA-CHM 2020) .[J] Am J Chin Med , 2020 , 48 ( 6 ): 1279 - 1313 .
BALSHEM H , HELFAND M , SCHÜNEMANN HJ , et al . GRADE guidelines: 3. Rating the quality of evidence [J]. J Clin Epidemiol , 2011 , 64 ( 4 ): 401 - 406 .
0
浏览量
0
下载量
14
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号